Parenteral biologics delivery: Recent progresses, key challenges and perspectives

European Journal of Parenteral and Pharmaceutical Sciences

Volumn 17, Issue 3, 2012, Pages 94-109

  Richard, Joël ^a  

^a IPSEN   (France)

Author keywords

Biodegradable polymer microparticles; Fusion proteins; Gelling formulations; Hydrogels; Long acting proteins; Nanoparticles; Parenteral biologics delivery; PEGylation; Polysialic acid conjugation; Protein post translational modifications; Protein sustained release formulations; Solid implants; Solvent free protein formulation technologies; Water based protein formulation technologies

Indexed keywords

ABATACEPT; AFLIBERCEPT; ALEFACEPT; ASPARAGINASE MACROGOL; CERTOLIZUMAB PEGOL; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ETANERCEPT; EYELEA; GELLING AGENT; HUMAN GROWTH HORMONE; IMMUNOGLOBULIN FC FRAGMENT; LEUPRORELIN; PEGADEMASE; PEGAPTANIB; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGINTERFERON BETA1A; PEGVISOMANT; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RILONACEPT; ROMIPLOSTIM; UNCLASSIFIED DRUG;

ACYLATION; ANGIOGENESIS; ANTIGEN BINDING; BINDING AFFINITY; BIODEGRADABILITY; CROSS LINKING; DRUG CLEARANCE; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG IMPLANT; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; ELECTROPHILICITY; ENCAPSULATION; GLOMERULUS FILTRATION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; KIDNEY CLEARANCE; LONG TERM CARE; MEDICATION COMPLIANCE; MOLECULAR WEIGHT; NONHUMAN; PALMITOYLATION; PATENT; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POROSITY; PROCESS DEVELOPMENT; PROTEIN DENATURATION; PROTEIN ENGINEERING; PROTEIN INTERACTION; PROTEIN PROCESSING; PROTEIN PURIFICATION; PROTEIN STABILITY; REVIEW; STEREOSPECIFICITY; SUSTAINED RELEASE FORMULATION; VISCOSITY;

EID: 84877793934     PISSN: 09644679     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Gronemann EN, Buckner P, et al. Biopharmaceuticals: entering a new world. In: Angle Report (Schmidt Helbirk I, Ed). Gentofte, Denmark: NNE Pharmaplan; 2012, p. 6.
2. Abuchowski A, McCoy JR, Palczuk NC, et al. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 1977; 252:3582-3586.
3. Maggon K. R&D paradigm shift and and billion-dollar biologics. In: Handbook of Pharmaceutical Biotechnology. Oxford: John Wiley; 2007, pp.161-198.
4. Jorgensen KE, Moller JV. Use of flexible polymers as probes of glomerular pore size. Am J Physiol 1979; 236:F103-F111.
5. Bailon P, Palleroni A, Schaffer CA, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol conjugated interferon α-2a for the treatment of hepatitis C. Bioconjug Chem 2001; 12:195-202.
6. Mager DE, Neuteboom B, Jusko WJ. Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys. Pharm Res 2005; 22:58-61.
7. Bowen S, Tare N, Inoue T, et al. Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein. Exp Haematol 1999; 27:425-432.
8. Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Rel 2000; 65:271-284.
9. Caliceti P, Chinol M, Roldo M, et al. Poly(ethylene glycol)-avidin bioconjugates: suitable candidates for tumor targeting. J Control Rel 2002; 83:97-108.
10. Morpurgo M, Veronese FM. Conjugates of peptides and proteins to poly ethylene glycols. Methods Mol Biol 2004; 283:45-70.
11. Morpurgo M, Veronese FM, Kachensky D, Harris JM. Preparation and characterization of polyethylene glycol vinyl sulfone. Bioconjug Chem 1996; 7:363-368.
12. Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 2002; 54:531-545.
13. Rosendahl MS, Doherty DH, Smith DJ, et al. Long-acting, highly potent interferon α-2 conjugate created using site-specific pegylation. Bioconjug Chem 2005; 16:200-207.
14. Del Rio A, Richard J. PEGylated interferon-beta formulations. European patent EP07150258.7 (2007); US patent 61/010,258 (2008); International patent PCT/EP/067876 (2009).
15. Lecolley F, Tao L, Mantovani G, et al. A new approach to bioconjugates for proteins and peptides (PEGylation) utilising living radical polymerisation. Chem Comm 2004; 18:2026-2027.
16. Greenwald RB, Yang K, Zhao H, et al. Controlled release of proteins from their poly(ethylene glycol) conjugates: drug delivery systems employing 1,6 elimination. Bioconjug Chem 1999; 14:395-403.
17. US National Institutes of Health. A safety, pharmacokinetic and pharmacodynamic study of ACP-001 (TransCon PEG hGH) in adults with growth hormone deficiency. ClinicalTrials. gov identifier: NCT01247675. Bethesda, MD, USA: US National Institutes of Health; 2011. Available online at www.clinicaltrials.gov
18. Fee C, Vanalstine J. PEG-proteins: reaction engineering and separation issues. Chem Eng Sci 2006; 61:924-939.
19. Sherman MR, Saifer MGP, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 2008; 60:59-68.
20. Ganson NJ, Kelly SJ, Scarlett E, et al. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 2006; 8(1):R12.
21. Webster R, Elliott V, Park BK, et al. PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals. In: PEGylated Protein Drugs: Basic Science and Clinical Applications (Veronese FM, Ed). Basel, Switzerland: Birkhauser Verlag; 2009, pp.127-146.
22. Fernandes AI, Gregoriadis G. The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: implication in its pharmacokinetics. Int J Pharm 2001; 217(1-2):215-224.
23. Jain S, Laing P, Gregoriadis G, et al. Sialic acid derivatives for protein derivatisation and conjugation. US Patent US 7,807,824 B2 (2010).
24. Laing P. Delivery of protein and peptide drugs with polysialic acid: a new technology platform in the clinic. Presentation at the 5th Annual Drug Delivery Systems Global Summit, London, UK, 22-23 September 2008.
25. Available online at www.fresenius-kabi.com
26. Lewis A, Tang Y, Brocchini S, et al. Poly(2-methacryloyloxyethyl phosphorylcholine) for protein conjugation. Bioconjug Chem 2008; 19:2144-2155.
27. Ahren B. GLP-1 for type 2 diabetes. Exp Cell Res 2011; 317:1239-1245.
28. Ghetie V, Popov S, Borvak J, et al. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nature Biotech 1997; 15:637-640.
29. Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 1991; 174:1483-1489.
30. de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, et al. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68:531-535.
31. Del Rio A, Rinaldi G, Richard J, Plitz T. TACI-immuglobulin fusion proteins for treatment of optic neuritis. European patent EP 07120490.3 (2007); US patent 61/002,988 (2007).
32. Sheridan C. Hemophilia market awaits next-generation therapies. Nature Biotech 2011; 29:960.
33. Fares FA, Suganuma N, Nishimori K, et al. Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin β subunit to the follitropin β subunit. Proc Natl Acad Sci USA 1992; 89:4304-4308.
34. Fares F, Ganem S, Hajouj T, Agai E. Development of a long-acting erythropoietin by fusing the carboxyl-terminal peptide of human chorionic gonadotropin β subunit to the coding sequence of human erythropoietin. Endocrinol 2007; 148:5081-5087.
35. Fares F, Guy R, Bar-Ilan A, et al. Designing a long-acting human growth hormone (hGH) by fusing the carboxyl-terminal peptide of human chorionic gonadotropin. subunit to the coding sequence of hGH. Endocrinol 2010; 151: 4410-4417.
36. European Medicines Agency/Committee for Medicinal Products for Human Use. CHMP assessment report for Elonva. EMA/CHMP/802299/2009. London: EMA/CHMP; 2009.
37. Chaudhury C, Brooks CL, Carter DC, et al. Albumin binding to FcRn: distinct from the FcRn-IgG interaction. Biochem 2006; 45:4983-4990.
38. Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotech 2011, 22:868-876.
39. Overly S. Human Genome Sciences expecting FDA to reject hepatitis C drug Zalbin. Available at www.wa s h i n g t o n p o s t. c om/wp d y n / c o n t e n t / a r t i c l e / 2010/06/14/AR2010061405373.html
40. Schulte S. Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa. Thromb Res 2008; 122:S14-S19.
41. Andersen JT, Daba MB, Berntzen G, et al. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J Biol Chem 2010; 285:4826-4836.
42. Wilkinson IR, Ferrandis E, Artymiuk PJ, et al. A ligand-receptor fusion of growth hormone forms a dimer and is a potent long-acting agonist. Nature Med 2007; 13:1108-1113.
43. Malik K, Singh I, Nagpal M, Arora S. Atrigel: a potential parenteral controlled drug delivery system. Der Pharmacia Sinica 2010; 1:74-81.
44. Rathi R, Elstad NL, Fowers KD. ReGel-a versatile controlled delivery system. Presentation at SMi Controlled Release Conference, London, UK, 11-12 March 2009.
45. Aaron DuVall G, Tarabar D, Seidel RH, et al. Phase 2: a doseescalation study of OncoGel (ReGel/paclitaxel), a controlled-release formulation of paclitaxel, as adjunctive local therapy to externalbeam radiation in patients with inoperable esophageal cancer. Anti-Cancer Drugs 2009; 20:89-95.
46. Okumu F. Novel excipients for sustained delivery of pharmaceutically active peptides and proteins. Presentation at 35th Controlled Release Society Meeting, New York, USA, 14 July 2008.
47. Chung HJ, Lee Y, Park TG. Thermo-sensitive and biodegradable hydrogels based on stereocomplexed pluronic multi-block copolymers for controlled protein delivery. J Control Rel 2008; 127:22-30.
48. Van Tomme SR, Storm G, Hennink WE. In situ gelling hydrogels for pharmaceutical and biomedical applications. Int J Pharm 2008; 355:1-18.
49. Lundstrom EA, Rencken RK, van Wyk JH, et al. Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer. Clin Drug Invest 2009; 29:757-765.
50. Crotts G, Park TG. Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues. J Microencapsulation 1998; 15:699-713.
51. Sinha VR, Trehan A. Biodegradable microspheres for protein delivery. J Control Rel 2003; 90:261-280.
52. He J, Feng M, Zhou X, et al. Stabilization and encapsulation of recombinant human erythropoietin into PLGA microspheres using human serum albumin as a stabilizer. Int J Pharm 2011; 416:69-76.
53. Johnson OL, Jaworowics W, Clelalnd JL, et al. The stabilization and encapsulation of human growth hormone into biodegradable microspheres. Pharm Res 1997; 14:730-735.
54. Jordan F, Naylor A, Kelly CA, et al. Sustained release hGH microsphere formulation produced by a novel supercritical fluid technology: in vivo studies. J Control Rel 2010; 141:153-160.
55. Stovall KD. Investigation of properties affecting controlled release of macromolecules from PLGA microspheres. PhD Thesis Dissertation, University of Illinois at Urbana-Champaign, USA; 2010.
56. van Dijkhuisen-Radersma R, Hesseling SC, Kaim PE, et al. Biocompatibility and degradation of poly(ether-ester) microspheres: in vitro and in vivo evaluation. Biomaterials 2002; 23:4719-4729.
57. Reithmeier H, Hermann J, Gopferich A. Lipid microparticles as a parenteral controlled release device for peptides. J Control Rel 2002; 73(2-3):339-350.
58. Maschke A, Becker C, Eyrich D, et al. Development of a spray congealing process fort he preparation of insulin-loaded lipid microparticles and characterization thereof. Eur J Pharm Biopharm 2002; 65:175-187.
59. Richard J, Fais F, Baldascini H. Solid lipid microcapsules containing hGH. International patent application WO/PCT/EP 2009/005826 (2009); WO 2010/017965 A2 (2010).
60. Richard J, Baldascini H, Agostinetto R, et al. Solid lipid microcapsules containing growth hormone inner core microparticles. International patent application WO 2009/080164 (2009).
61. Richard J, Deschamps F, De Conti AM, et al. Use of glycerol dipalmitostearate for improving the bioavailability of protein active ingredients in subcutaneous or intramuscular injectable formulations. International patent application WO2005/099767 (2005).
62. Govardhan C, Khalaf N, Jung CW, et al. Novel long-acting crystal formulation of human growth hormone. Pharm Res 2005; 22:1461-1470.
63. Bos GW, Verrijk R, Franssen O, et al. Controlled release of pharmaceutical proteins. Pharm Technol 2001; 10:118-120.
64. Vlugt-Wensink KDF, de Vrueh R, Gresnigt MG, et al. Preclinical and clinical in vitro in vivo correlation of an hGH dextran microsphere formulation. Pharm Res 2007; 24:2239-2248.
65. Chan Y-P, Meyrueix R, Kravtzoff R, et al. Review on Medusa®: a polymer-based sustained release technology for protein and peptide drugs. Exp Opin Drug Deliv 2007; 4:441-451.
66. Kim SJ, Hahn SK, Kim MJ, et al. Development of a novel sustained release formulation of recombinant human growth hormone using sodium hyaluronate microparticles. J Control Rel 2005; 104:323-335.
67. Bidlingmaier M, Kim J, Savoy C, et al. Comparative pharmacokinetics and pharmacodynamics of a new sustainedrelease growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency. J Clin Endocrinol Metab 2006; 91:2926-2930.
68. Peter F, Bidlingmaier M, Savoy C, et al. Three-year efficacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH deficiency (GHD). J Clin Endocrinol Metab 2012; 97:400-407
69. Rohloff CM, Alessi TR, Yang B, et al. DUROS® technology delivers peptides and proteins at consistent rate continuously for 3 to 12 months. J Diabetes Sci Technol 2008; 2:461-467.
70. Fowler Jr JE, Viadur Study Group. Patient-reported experience with the Viadur 12 month leuprolide implant for prostate cancer. Urology 2001; 58:430-434.
71. Wu F, Jin T. Polymer-based sustained-release dosage forms for protein drugs, challenges and recent advances. AAPS PharmSciTech 2008; 9:1218-1229.
72. Maji SK, Schubert D, Rivier C, et al. Amyloid as a depot for the fomulation of long-acting drugs. PLoS Biology 2008; 6:0240-0252.
73. van Grondelle W, Lopez Iglesias C, Coll E, et al. Spontaneous fibrillation of the native meuropeptide hormone Somatostatin-14. J Struct Biol 2007; 160:211-223.
74. Dannies PS. Protein hormone storage in secretory granules: mechanisms for concentration and sorting. Endo Rev 1999; 20:3-21.
75. Maji SK, Perrin MH, Sawaya MR, et al. Functional amyloids as natural storage of peptide hormones in pituitary secretory granules. Science 2009; 325:328-332.
76. Park K, Kwon IC, Park K. Oral protein delivery: current status and future prospect. Reactive Functional Polymers 2001; 71:280-287.